Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Statin Induced Myopathy
BMJ 337:1159-1162, Sathasivam,S. &Lecky,B., 2008
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
Statin-Associated Myopathy
JAMA 289:1681-1690, Thompson,P.D.,et al, 2003
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
AAC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Stroke 33:2337-2341, Pasternak,R.C.,et al, 2002
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
Inclusion Body Myositis, Observations in 40 Patients
Brain 112:727-747, Lotz,B.P.,et al, 1989
Labetalol-induced Toxic Myopathy
BMJ 282:1824-1825, Teicher,A.,et al, 1981
Neuropsychiatric Manifest. of SLE:Diagnosis, Clinical Spectrum, & Relationship to Other Features of the Disease
Medicine 55:323, Feinglass,E.J.,et al, 1976
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975
A 31-year-Old Man with Bilateral Limited Mobility of Joints
JAMA Neurol 79:1083-1084, Wang, Z.,et al, 2022
Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies
Medicine 92:15-24, Fernandez, C.,et al, 2013
The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies
Medicine 92:223-243, Rider, L.,et al, 2013
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
A Case of Necrotizing Myopathy with Proximal Weakness and Cardiomayopathy
Neurol 78:1527-1532, Matthews,E.,et al, 2012
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients with Idiopathic Inflammatory Myopathy
Medicine 89:47-52, Trallero-Araguas,E.,et al, 2010
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia Gravis
Arch Neurol 66:1334-1338, 1322, Suzuki,S.,et al, 2009
Diagnostic Evaluation of Clinically Normal Subjects with Chronic hyperCKemia
Neurol 66:1585-1587, Fernandez,C.,et al, 2006
Fatal Myositis Due to the Microsporidian Brachiola algerae, a Mosquito Pathogen
NEJM 351:42-47, Coyle,C.M.,et al, 2004
Focal, Steroid Responsive Myositis Causing Dropped Head Syndrome
Muscle & Nerve 22:769-771, Biran,I.,et al, 1999
Weak at the Knees
Lancet 354:1696, Webster,G.&Beynon,H., 1999
Inflammatory Myopathy in Thyrotoxicosis
Neurol 48:339-341, Hardiman,O.,et al, 1997
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Inclusion Body Myositis:Clinical and Pathological Boundaries
Ann Neurol 40:581-586, Amato,A.A.,et al, 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Inclusion Body Myositis Presenting with Isolated Erector Spinae Paresis
Neurol 45:993-994, Hund,E.,et al, 1995
Common Variable Immunodeficiency and Inclusion Body Myositis:A Distinct Myopathy Mediated by Natural Killer Cells
Ann Neurol 37:806-810, Dalakas,M.C.&Illa,I., 1995
Drug Therapy of Idiopathic Inflammatory Myopathies:Response to Prednisone Azathioprine, & Methotrexate
Am J Med 94:379-387, Joffe,M.M.,et al, 1993
Treatment of Inclusion-Body Myositis with High-Dose Intravenous Immunoglobulin
Neurol 43:876-879, Soueidan,S.A.&Dalakas,M.C., 1993
Generalized Myositis in Behcet Disease:TReatment with Cyclosporine
Ann Int Med 116:651-653, Lingenfelser,T.,et al, 1992
Pravastatin-Associated Inflammatory Myopathy
NEJM 327:649-650, Schalke,B.B.,et al, 1992
Neurologic Manifestations of Progressive Systemic Sclerosis
Arch Neurol 49:1292-1295, Averbuch-Heller,L.,et al, 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Myopathy Associated with Ketoconazole Treatment
Am J Dis Child 145:970-971, Garty,B-Z.,et al, 1991
Legionella Myositis
Neurol 41:750-752, Warner,C.L.,et al, 1991